null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Ontamalimab ELISA Kit (GXEL00208)

SKU GXEL00208
Product Type ELISA Kit
Assay Type Quantitative
Detection Method Colorimetric
Sensitivity 0.156 μg/ml
Range 0.31-5 μg/mL
Size 96T
Synonyms PF-00547659, PF-547659, SHP647, 2098790-40-8
€880
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Ontamalimab ELISA Kit

Assay Genie's Ontamalimab ELISA Kit (SKU: GXEL00208) provides researchers with a reliable quantitative ELISA for the quantitative measurement of Ontamalimab in Plasma, Serum. Offering a measurement range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml, the kit is optimised for precision and ease of use in the research laboratory.

Ontamalimab (SHP647) is a fully human, immunoglobulin G2 , antihuman mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody being developed for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). A population pharmacokinetic/pharmacodynamic (PK/PD) analysis was conducted using clinical phase 2 study data to evaluate the PK and PD of ontamalimab following subcutaneous administrations of 7.5, 22.5, 75, and 225 mg every 4 weeks in patients with moderate to severe UC or CD. A total of 440 patients with UC (n = 249; 56.6%) or CD (n = 191; 43.4%) were included in the analysis. A 2-compartment model with parallel linear and nonlinear elimination adequately characterized concentration-time profiles of ontamalimab. The apparent clearance and volume of distribution were 0.0127 L/h (0.305 L/day) and 6.53 L, respectively. Apparent clearance and volume of distribution were mainly dependent on baseline albumin and body weight, respectively. No differences in the PK properties of ontamalimab were observed between patients with UC or CD. The presence of antidrug antibodies did not impact the PK of ontamalimab. Nonlinear elimination occurred at very low concentrations and was unlikely to contribute to the elimination half-life under steady-state conditions. A linear PK/PD model described the relationship between ontamalimab and free MAdCAM-1. Minimum concentrations of ontamalimab at steady state following 75 mg every 4 weeks were associated with >95% suppression of circulating free MAdCAM-1. The PK/PD properties characterized support phase 3 testing in UC and CD.

Complete with standards, buffers and detection reagents, the Ontamalimab ELISA Kit streamlines assay set-up so you can focus on results. Choose the Ontamalimab ELISA Kit from Assay Genie for quality you can trust.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose